- Price
- $83.59
- Day
- +0.43%
- Mkt Cap
- $9.91B
- 52W Range
- $61.23 – $84.44
- Volume
- 1.26M
- Beta
- 0.84
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Halozyme (HALO) has delivered ~134% price appreciation since my prior 'Buy' rating in 06/2023. I evaluate whether HALO can sustain its strong growth trajectory or is due for a period of consolidation. The investment thesis centers on HALO's robust royalty revenue and product income as key growth drivers.
Read full article
This medical technology name has a patented method of drug delivery. Halozyme stock recently hit a record high with earnings due out soon.
Read full article
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) shares reached a new 52-week high on Friday. The company traded as high as $82.99 and last traded at $81.5140, with a volume of 217609 shares trading hands. The stock had previously closed at $80.84. Analyst Ratings Changes HALO has been the topic of several analyst
Read full article
SAN DIEGO, July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, following the close of trading. Halozyme will host a conference call on Thursday, August 6, 2026 at 1:30pm PT/4:30pm ET to discuss the results.
Read full article
Halozyme Therapeutics, Inc. (HALO) shares gain 539% since first Big Money outlier inflow signal in March 2014.
Read full article
Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.
Read full article
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets SAN DIEGO, July 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs), utilizing Halozyme's proprietary ENHANZE® drug delivery technology. The collaboration will focus on the potential for ENHANZE® to strengthen the subcutaneous formulation currently in development for INCA033989, with the goal of enabling more convenient delivery and dosing regimens that may improve the treatment experience.
Read full article
Fifth Third Bancorp increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 4,206.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 68,128 shares of the biopharmaceutical company's stock after acquiring an additional 66,546 shares during the quarter. Fifth Third Bancorp
Read full article
HALO stocks are gaining favor as investors rotate toward tangible assets and AI-resistant businesses. Here are ETFs to play the trend.
Read full article
ARCO, HALO, TX and ARRY screen as high-earnings-yield value picks as the Middle-East conflict sharpens stock selection.
Read full article